AU2002339696A8 - Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors - Google Patents

Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors

Info

Publication number
AU2002339696A8
AU2002339696A8 AU2002339696A AU2002339696A AU2002339696A8 AU 2002339696 A8 AU2002339696 A8 AU 2002339696A8 AU 2002339696 A AU2002339696 A AU 2002339696A AU 2002339696 A AU2002339696 A AU 2002339696A AU 2002339696 A8 AU2002339696 A8 AU 2002339696A8
Authority
AU
Australia
Prior art keywords
treatment
oxidase
amino acid
cns disorders
aspartate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339696A
Other versions
AU2002339696A1 (en
Inventor
Paul Moser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Publication of AU2002339696A8 publication Critical patent/AU2002339696A8/en
Publication of AU2002339696A1 publication Critical patent/AU2002339696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002339696A 2001-12-03 2002-10-29 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors Abandoned AU2002339696A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33658301P 2001-12-03 2001-12-03
US60/336,583 2001-12-03
PCT/IB2002/004805 WO2003047558A2 (en) 2001-12-03 2002-10-29 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors

Publications (2)

Publication Number Publication Date
AU2002339696A8 true AU2002339696A8 (en) 2003-06-17
AU2002339696A1 AU2002339696A1 (en) 2003-06-17

Family

ID=23316743

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339696A Abandoned AU2002339696A1 (en) 2001-12-03 2002-10-29 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors

Country Status (2)

Country Link
AU (1) AU2002339696A1 (en)
WO (1) WO2003047558A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110339A2 (en) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Method for selective targeting of apoptotic cells and small molecule ligands used thereof
CA2472806A1 (en) 2004-05-18 2005-11-18 Petro-Canada Compositions and methods for treating turf insect pests and diseases such as fungal infestations
US20060111442A1 (en) * 2004-11-20 2006-05-25 Mr. Stanley Antosh Use of methyl pyruvate to increase cellular energy production downstream of glycolysis for the PARP-1 ablation of HIV without necrotic cell death caused by continuous, chronic PARP-1 activation through the concomitant depletion of ATP and NAD.
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
US9357768B2 (en) 2006-10-05 2016-06-07 Suncor Energy Inc. Herbicidal composition with increased herbicidal efficacy
FR2929115B1 (en) * 2008-03-31 2010-06-04 Exsymol Sa COSMETIC USE OF CONJUGATED COMPOUNDS OF INDOLIC AUXINS.
US8569210B2 (en) 2008-06-26 2013-10-29 Suncor Energy Inc. Turfgrass fungicide formulation with pigment
EP2389187B1 (en) 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
CN103338642A (en) 2010-09-09 2013-10-02 桑科能源股份有限公司 Synergistic paraffinic oil and boscalid fungicides
JO3115B1 (en) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors
US8791045B2 (en) 2011-11-09 2014-07-29 Kimberly-Clark Worldwide, Inc. Non-tacky wetness indicator composition for application on a polymeric substrate
US9889222B2 (en) 2011-11-09 2018-02-13 Kimberly-Clark Worldwide, Inc. Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness
JP6169492B2 (en) 2011-11-15 2017-07-26 武田薬品工業株式会社 Dihydroxy aromatic heterocyclic compounds
US9585826B2 (en) 2012-11-07 2017-03-07 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of active chemistry
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9119780B2 (en) 2013-10-30 2015-09-01 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of proactive chemistry
GB201403944D0 (en) * 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
BR112017025499A2 (en) * 2015-05-28 2018-08-07 Baylor College Medicine Benefits Of N-Acetyl Cysteine And Glycine Supplementation To Improve Glutathione Levels
CA2938096C (en) 2016-08-04 2019-02-26 Suncor Energy Inc. Stabilized emulsions
CN108420810A (en) * 2018-02-11 2018-08-21 华南农业大学 Phenylpyruvic acid is preparing the application in alleviating or improving the product of anxiety and Depressive behavior
RU2751003C1 (en) * 2020-07-29 2021-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В.Ломоносова» (МГУ) Use of sulfonates for inhibiting human lactate dehydrogenase a
CN115745848A (en) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 Processing and synthesizing process of aminoguanidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012923B2 (en) * 1998-01-26 2000-02-28 新潟大学長 Drug for treating CAG repeat disease
AU4823999A (en) * 1998-06-17 2000-01-05 Yeda Research And Development Co. Ltd. Methods and compositions for treating diseases mediated by transglutaminase activity
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
IL156865A0 (en) * 2001-01-16 2004-02-08 Genset Sa D-amino acid oxidase and d-aspartate oxidase for use in cns disorders

Also Published As

Publication number Publication date
WO2003047558A3 (en) 2004-03-25
WO2003047558A2 (en) 2003-06-12
AU2002339696A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
AU2002339696A8 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
MXPA03006321A (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists.
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
EP1383743A4 (en) Dual inhibitors of pde 7 and pde 4
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL153766A0 (en) Inhibitors of copper-containing amine oxidases
EP1448218A4 (en) Beta-secretase inhibitors and methods of use
AU9411701A (en) Combination use of acetylcholinesterase inhibitors and gaba<sub>A</sub> inverse agonists for the treatment of cognitive disorders
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
GB0121155D0 (en) Treatment of substrates
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
EP1443919A4 (en) Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
HK1063721A1 (en) Quinolone carboxylic acid compositions and related methods of treatment
AU2003249645A8 (en) Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
TWI318878B (en) Quinolone carboxylic acid compositions and related methods of treatment
IL157176A0 (en) Purification of 2-nitro-4-methylsulphonylbenzoic acid
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
PL375631A1 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
IL161741A0 (en) Methods of reversing and preventingcardiovascular pathologies
AU2002246926A1 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
AU3712500A (en) Compositions and methods for treatment of epilepsy
HK1062806A1 (en) Novel methods for the treatment and prevention of pain using stress- activated protein kinase inhibitors
IL158413A0 (en) Treatment of adhd

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase